Form 4: SI-BONE Director Jeryl L. Hilleman Granted 8,675 Restricted Stock Units

SI-BONE, Inc. Director Jeryl L. Hilleman was granted 8,675 restricted stock units (RSUs) on June 5, 2025, as part of her compensation, which will vest upon continued service.

Summary

• Jeryl L. Hilleman, a Director of SI-BONE, Inc. (SIBN), acquired 8,675 shares of common stock on June 5, 2025.
• These shares represent restricted stock units (RSUs) granted to the Reporting Person.
• Each RSU signifies a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date, contingent on continuous service as a Board member.
• Following this transaction, Jeryl L. Hilleman beneficially owns 32,815 shares, which includes the newly granted 8,675 RSUs.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is generally a positive sign of continued alignment between management/board and shareholder interests. There are no negative financial implications or operational concerns raised.

Positives

• The grant of restricted stock units aligns the interests of the director, Jeryl L. Hilleman, with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and continuous service from the director to the company's Board.

Negatives

• The transaction itself does not present any explicit negatives, as it is a standard form of equity compensation for directors.

Risks

• The value of the granted restricted stock units is subject to the future performance of SI-BONE, Inc.'s common stock, meaning the actual realized value could be lower than the grant date value if the stock price declines.

Future Outlook

The document indicates that the granted restricted stock units will vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date, subject to the director's continuous service.

Industry Context

This transaction is a routine equity compensation event for a director in a publicly traded medical device company like SI-BONE, Inc., reflecting standard practices for aligning executive and board incentives with shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) as part of director compensation is a common practice across publicly traded companies, including those in the medical device sector, aligning director incentives with long-term shareholder value.
• The vesting schedule, tied to continued service and a specific timeframe (annual meeting or one year), is typical for such grants, comparable to similar arrangements at companies like NuVasive, Inc. or Globus Medical, Inc. for their non-employee directors.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Jeryl L. Hilleman, a director of SI-BONE, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director is intended to align the director's interests with shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: No direct impact on employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated by this specific filing.
• Suppliers: No direct impact on suppliers is indicated by this specific filing.
• Creditors: No direct impact on creditors is indicated by this specific filing.

Next Steps

• The restricted stock units are expected to vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date, provided Jeryl L. Hilleman maintains continuous service as a Board member.

Key Dates

Keywords

SI-BONE, SIBN, Restricted Stock Units, RSU, Director Compensation, Equity Grant, SEC Form 4, Insider Transaction, Corporate Governance